Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Revolution Medicines, Inc.NASDAQ: RVMD
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables dips below year-ago levels
Q2 FY2026 accounts payables of $5.03M fell 42.6% year over year, behind the +14.3% change in trailing-twelve-month accounts payables. Sequentially, it fell 70.2% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -42.6% toward the trailing-twelve-month pace of +14.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 9.54M USD
- Year-over-year change
- +247.5%
- 4-year CAGR
- +43.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.54M | +247.5% |
| FY2024 | 2024-12-31 | (6.47M) | -119.9% |
| FY2023 | 2023-12-31 | 32.47M | +345.5% |
| FY2022 | 2022-12-31 | 7.29M | +225.5% |
| FY2021 | 2021-12-31 | 2.24M | — |
Accounts Payables vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's LTM Jun 2026 accounts payables of $30.93M is the largest of the 11 companies compared; the peer median is $1.1M.
- Its year-over-year change of +14.3% is the 7th highest of 11, against a peer median of +32.2%.
- Over three fiscal years its annual growth of +9.4% compares with a peer median of +25.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $30.93M | +14.3% | +9.4% | — | |
| LTM Aug 2026 | $25.05M | +537.3% | — | 3.6% | |
| LTM Jun 2026 | $7.04M | -374.8% | — | 68.0% | |
| LTM Mar 2026 | $3.02M | -73.7% | +13.1% | 1.3% | |
| LTM Mar 2026 | $2.4M | +1061.2% | +48.0% | 4.8% | |
| LTM Mar 2026 | $1.54M | +244.4% | +164.1% | 3.6% | |
| LTM Sep 2026 | $1.4M | +348.4% | +25.7% | — | |
| LTM Sep 2026 | $798K | +27.9% | -8.8% | — | |
| LTM Mar 2026 | $448K | +36.6% | +70.0% | — | |
| LTM Sep 2026 | $365K | -82.6% | — | — | |
| LTM Mar 2026 | $341K | -76.2% | +15.4% | — | |
| Peer median (excluding RVMD) | $1.1M | +32.2% | +25.7% | 3.6% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (187.09M) | (248.71M) | (436.37M) | (600.09M) | (1.13B) |
| Depreciation & Amortization | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| Deferred Income Tax | 0 | (419K) | (3.91M) | (762K) | 0 |
| Stock-Based Compensation | 20.72M | 31.2M | 61.77M | 79.2M | 118.39M |
| Change in Working Capital | 8.72M | (13.49M) | 40.66M | 1.17M | 86.82M |
| Accounts Receivables | 464K | 1.26M | 3.42M | 1.25M | 0 |
| Inventory | 7.68M | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.24M | 7.29M | 32.47M | (6.47M) | 9.54M |
| Other Working Capital | (1.66M) | (22.03M) | 4.77M | 6.38M | 77.29M |
| Other Non-Cash Items | 3.13M | (2.64M) | (22.04M) | (48.77M) | 11.79M |
| Operating Cash Flow | (147.18M) | (224.4M) | (350.57M) | (557.44M) | (897.74M) |
| Capital Expenditures | (6.53M) | (10.82M) | (7.73M) | (10.31M) | (15.99M) |
| Acquisitions (Net) | 135.59M | 13.3M | 0 | 0 | 0 |
| Purchases of Investments | (671.34M) | (612.77M) | (1.06B) | (2.14B) | (1.79B) |
| Sales of Investments | 535.75M | 599.47M | 724.05M | 1.59B | 1.93B |
| Other Investing Activities | (135.59M) | (13.3M) | 0 | 0 | 0 |
| Investing Cash Flow | (142.12M) | (24.12M) | (342.6M) | (554.39M) | 118.06M |
| Debt Repayment | 0 | 0 | 0 | 0 | 244.22M |
| Common Stock Issued | 291.24M | 298.05M | 392.39M | 959.13M | 377.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.94M | 3.39M | 836.81M | 284K | 220K |
| Financing Cash Flow | 294.18M | 301.43M | 1.23B | 959.41M | 621.52M |
| Effect of Forex Changes | 0 | 0 | (1.29M) | (667K) | 0 |
| Net Change in Cash | 4.88M | 52.92M | 534.74M | (153.08M) | (158.16M) |
| Free Cash Flow | (153.71M) | (235.22M) | (358.3M) | (567.74M) | (913.73M) |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.